Aelis Farma : Initial evidence of efficacy in cognitive disorders
>Positive results in phase I/II of AEF0217 in Down’s syndrome - Last night we learned of the initial positive results of Aelis’ phase I/II trial evaluating AEF0217 in Down's syndrome (trisomy 21). The trial had two objectives: first, to demonstrate safety for patients, and second, to provide an initial proof of concept and efficacy. There were no notable side-effects. Adverse events were similar in the placebo and AEF0217 groups. Most of the adverse events observ...
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.